Exhibit 99.1 ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update Positive, Statistically Significant Real-World Health Outcomes Demonstrated for ASCENIV™ Record ASCENIV Demand and Anticipated 2026 Payer Coverage Expansion Support Sustained and Accelerating Revenue Growth Trajectory Advancing SG-001 Pipeline Program and CNPV Voucher Application Submitted; Strengthen Long-Term Pipeline Outlook Ongoing Share Repurchases and Strengthened Capital Structure Support Long-Term ...